Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
This is a treatment study trial, in which we will assess the safety and tolerability of daily dose IL-2, as monotherapy for 12 weeks, followed by IL2 in combination with PEG-IFN and RBV for 48 weeks in the treatment of chronic Hepatitis C.
Epistemonikos ID: 8d459db883c51acc0b82944bb4c6adfa563e70fc
First added on: Mar 23, 2020